Targeted Pharmaceuticals

Targeted Pharmaceuticals is a clinical-stage biopharmaceutical company using synthetic and other cannabinoids to modulate autophagy and related pathways in oncology and CNS disorders. It reports an awarded patent covering use of any molecule, including cannabinoids, as an autophagy inhibitor for cancer, provisional patents for multiple CNS-related viruses and diseases, and 15+ cell studies in oncology and antiviral/CNS indications. Ongoing Phase I/II clinical trials are described in ductal carcinoma in situ (DCIS) breast cancer and HIV-associated dementia, plus preclinical antiviral work in sepsis, including COVID-related sepsis, conducted in collaboration with a BSL-3 laboratory at George Mason University.[1][3]